|1.||Goetz, Matthew P: 10 articles (04/2015 - 12/2005)|
|2.||Ingle, James N: 8 articles (04/2015 - 12/2005)|
|3.||Ames, Matthew M: 6 articles (04/2015 - 12/2005)|
|4.||Safgren, Stephanie L: 5 articles (04/2015 - 12/2005)|
|5.||Zembutsu, Hitoshi: 5 articles (01/2015 - 05/2008)|
|6.||Flockhart, David A: 5 articles (12/2014 - 05/2005)|
|7.||Teft, Wendy A: 5 articles (07/2014 - 03/2011)|
|8.||Kim, Richard B: 5 articles (07/2014 - 03/2011)|
|9.||Spelsberg, Thomas C: 5 articles (01/2014 - 03/2009)|
|10.||Hawse, John R: 5 articles (01/2014 - 03/2009)|
|1.||Breast Neoplasms (Breast Cancer)
02/01/2014 - "Endoxifen shows promise in breast cancer."
03/01/2015 - "The relationship between endoxifen levels and breast cancer outcomes has to be replicated and confirmed and the value of TDM should be evaluated in prospective clinical trials. "
01/01/2014 - "These studies are the first to examine the in vivo and in vitro impacts of endoxifen on bone and our results demonstrate that endoxifen increases cancellous as well as cortical bone mass in ovariectomized mice, effects that may have implications for postmenopausal breast cancer patients. "
01/01/2014 - "Based on past studies in breast cancer cells and model systems, endoxifen classically functions as an anti-estrogenic compound. "
04/01/2012 - "Lower concentrations of endoxifen have been associated with inferior breast cancer outcomes in numerous retrospective trials. "
05/01/2013 - "It is anticipated that endoxifen concentration achieved in individual patients is the limiting factor for achieving optimal tumor growth suppression."
05/01/2013 - "Subsequently, simulations using human PK were used to determine the efficacious clinically relevant endoxifen concentration required to produce optimal tumor suppression. "
05/01/2013 - "However, the relationship between endoxifen exposure and tumor growth inhibition has not been well-characterized and little is known regarding the optimal in vivo endoxifen plasma level required for tumor inhibition. "
07/01/2015 - "ZB483 was demonstrated to be more efficacious than endoxifen in inhibiting xenograft tumor growth in mice at equal dosage but more so at lower dosage. "
01/01/2014 - "In the MCF-7 human mammary tumor xenograft model with female athymic mice, (Z)-endoxifen, at an oral dose of 4⬜8 mg/kg, significantly inhibits tumor growth. "
06/01/2014 - "However, CYP3A4*22 carriers were less likely to have hot flashes with an odds ratio of 8.87 (p < 0.01) even when compared to a cohort with similar endoxifen levels. "
06/01/2014 - "It remains unclear whether the extent of attained endoxifen level or genetic polymorphisms in drug metabolizing enzymes is associated with the frequency and severity of hot flashes. "
12/20/2005 - "In tamoxifen-treated patients, women with the CYP2D6 *4/*4 genotype tend to have a higher risk of disease relapse and a lower incidence of hot flashes, which is consistent with our previous observation that CYP2D6 is responsible for the metabolic activation of tamoxifen to endoxifen."
|4.||Melanoma (Melanoma, Malignant)
09/05/2013 - "Altogether, our results show for the first time that a combined treatment of all-trans-retinoic acid with endoxifen may provide an anti-proliferative and anti-migration effect upon melanoma cells without major toxicity, offering a powerful therapeutic strategy for malignant melanoma."
09/05/2013 - "Moreover, the combination of all-trans-retinoic acid with endoxifen significantly decreased melanoma cells migration, whereas the combination with tamoxifen did not present significant effects. "
09/05/2013 - "The combination of the antiestrogen endoxifen with all-trans-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells."
09/05/2013 - "Thus, we investigated the effects of all-trans-retinoic acid combined with the antiestrogen endoxifen on melanoma cell proliferation and the effects were compared with its pro-drug tamoxifen. "
10/05/2015 - "On one hand, it is now believed that metabolism is a major determinant of tamoxifen clinical outcomes in breast cancer patients, which is a variable that has yet to be tested in melanoma patients, since the tamoxifen active metabolite endoxifen demonstrated superior cytostatic activity over the parent drug in melanoma cells; on the other hand, new evidence has emerged regarding estrogen-mediated signaling in melanoma cells, including the methylation of the estrogen receptor-α gene promoter and the expression of the G protein coupled estrogen receptor. "
|5.||Colorectal Neoplasms (Colorectal Cancer)
|2.||Cytochrome P-450 CYP2D6 (CYP2D6)
|6.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|1.||Heterologous Transplantation (Xenotransplantation)